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Abstract 
Presenilin 1 (PSEN1) mutations are the main cause of autosomal dominant early onset 
Alzheimer Disease (EOAD). Among them, deletions of exon 9 have been reported to be 
associated with a phenotype of spastic paraparesis.  
Using exome data from a large sample of 522 EOAD cases and 584 controls to search for 
genomic copy-number variations (CNVs), we report here a novel partial, in-frame deletion of 
PSEN1, removing both exons 9 and 10. The patient presented with memory impairment 
associated with spastic paraparesis, both starting from the age of 56 years. He presented a 
positive family history of EOAD. We performed functional analysis to elucidate the impact of 
this novel deletion on PSEN1 activity as part of the γ-secretase complex. The deletion does 
not affect the assembly of a mature protease complex but has an extreme impact on its global 
endopeptidase activity. The mutant carboxypeptidase-like activity is also strongly impaired 
and the deleterious mutant effect leads to an incomplete digestion of long Aβ peptides and 
enhances the production of Aβ43, which has been shown to be potently amyloidogenic and 
neurotoxic in vivo.  
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Introduction: 
Mutations in the Amyloid Precursor protein (APP), Presenilin 1 (PSEN1) and Presenilin 2 
(PSEN2) genes and duplications of the APP locus are the main causes of Autosomal 
Dominant Early-onset Alzheimer’s disease (AD-EOAD). Mutations in the PSEN1 gene 
account for the majority of AD-EOAD cases with 221 pathogenic mutations reported to date 
(http://www.alzforum.org/), including 6 deletions of PSEN1 exon 9 resulting either from 
splicing mutations (Perez-Tur et al., 1995; Sato et al., 1998; Rovelet-Lecrux et al., 2015) or 
genomic deletions (Prihar et al., 1999; Hiltunen et al., 2000; Smith et al., 2001). 
 
Presenilin is the catalytic subunit of the γ-secretase, an enzymatic complex involved in the 
processing of numerous type 1 transmembrane proteins, including APP and Notch (Jurisch-
Yaksi et al., 2013). The sequential cleavage of APP by the β- and γ-secretase releases the Aβ 
peptides of different lengths. The accumulation of aggregation-prone Aβ peptides into senile 
plaques is central to AD pathophysiology. The γ-secretase cleavage occurs in a multi-step 
process: first, the endopeptidase (ε) cleavage releases the C-terminal part of APP (AICD) and, 
depending on the position of the ε-cleavage, either the Aβ49 or Aβ48 fragment will be 
produced. Then, carboxypeptidase-like γ-cleavages sequentially shorten these Aβ peptides 
following specific lines of production: Aβ49->Aβ46->Aβ43->Aβ40->Aβ37 and Aβ48-
>Aβ45->Aβ42->Aβ38 (Takami et al., 2009). AD-linked PSEN1 variations result in various 
effects on γ-secretase activity: whereas the endopeptidase cleavage is not always impaired, the 
carboxypeptidase efficiency is consistently reduced, resulting in qualitative shifts in Aβ 
profile, favoring the secretion of longer, more aggregation-prone Aβ peptides such as Aβ42 
and Aβ43, and possibly longer (Saito et al., 2011; Chávez-Gutiérrez et al., 2012; Szaruga et 
al., 2015; Veugelen et al., 2016). 
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In the present study, we used exome sequencing data from a large cohort of 522 EOAD cases 
and 584 controls to search for genomic copy-number variations (CNVs). We identified a 
novel mutation consisting of a genomic deletion of exons 9 and 10 of PSEN1 in an EOAD 
patient and evaluated the consequences of this variation on γ-secretase activity. The deletion 
of exons 9-10 drastically decreases the global endopeptidase activity and results in an 
increased secretion of Aβ43. Following previous work demonstrating that other highly 
inactivating PSEN1 mutations show similar effects on Aβ secretion (Veugelen et al., 2016), 
the data presented here further supports the pathogenic role of Aβ43, even at low 
concentrations. 
 
MATERIALS AND METHODS 
Patients, whole exome sequencing, and CNV calling 
We performed whole exome sequencing (WES) in 546 patients with EOAD and 597 controls 
from French ancestry. Inclusion of patients and controls, WES details, bioinformatics 
pipelines and quality checks (QC) were previously reported (Nicolas et al., 2016b). Briefly, 
diagnoses of probable AD were performed according to the NIA-AA recommendations 
(McKhann et al., 2011) and genetic diagnosis of mutation in AD-causative genes were 
first made prior to WES if our national criteria were met (i.e. two cases from the same 
family with AAO before 65 or sporadic case with AAO before 50) (Nicolas et al., 2016a). 
Screening of AD-causative CNVs was routinely performed for APP duplication 
following same criteria. 
For 385 EOAD patients, cerebrospinal fluid (CSF) total-Tau, Phosphorylated-Tau, and Aβ42 
biomarkers were available and were all indicative of AD pathophysiology (Le Guennec et al., 
2016a). The mean age at onset was 55 years (range 44-65). Out of the 546 initially included 
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cases and 597 controls, 535 cases and 593 controls passed the QC for genetic case-control 
association analyses and were retained for CNV calling.  
CNV calling was performed using the CANOES software (Backenroth et al., 2014), an 
algorithm dedicated to the detection of quantitative genomic variations based on read depth 
information. A final sample of 522 patients and 584 controls passed the quality criteria for 
CNV calling. A total of 13,870 CNVs were called in these 1106 samples. Note that, as 
CNV calling by CANOES is based on read depth, only rare events are efficiently 
detected. Previous validation of this software using aCGH data revealed a high 
concordance (88%) between the two methods, and showed that CANOES specifically 
missed a subset of very small monoexonic CNVs with lower read depth (Le Guennec et 
al., 2016b). 
 
Quantitative Multiplex PCR of Short Fluorescent Fragments (QMPSF) 
Genomic DNA was extracted from blood samples using the Flexigen DNA kit (Qiagen, 
Hilden, Germany). PSEN1 exon 9/10 deletion was validated according to an already 
published process using QMPSF spanning exons 1, 7 and 18 of APP (Rovelet-Lecrux et 
al., 2006) to which we added two supplemental amplicons spanning exons 9 and 10 of 
PSEN1. Primers are available upon request. DNA fragments were then separated on an ABI 
3500 genetic analyzer. The fluorescence profiles were analyzed using the GeneMapper 
software 5 (Applied Biosystems). 
 
Breakpoint sequencing 
After delineation of the deletion by QMPSF using amplicons located in introns 8 and 10 of 
PSEN1, the rearranged allele was PCR-amplified and Sanger sequenced using the following 
primers: F-5’-AGTGTATTGCCTGCCTGGTTTC-3’ and R-5’-
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CTGGCTGTTGCTGAGGCTTT-3’. DNA sequences were run on an ABI 3500 genetic 
analyzer and analyzed using the Sequencing Analysis Software 6 (Applied Biosystems). 
 
RT-PCR analysis 
Total RNA was extracted from whole blood collected into PAXgene Blood RNA tubes using 
the PAXgene Blood RNA kit (Qiagen, Hilden, Germany). RNA was reverse-transcribed using 
the Verso cDNA synthesis kit (Fisher Scientific, Illkirch, France) with a blend of random 
hexamers and anchored oligo-dT (3:1). The cDNA were then PCR-amplified using the 
following primers: F-5’-GTGGCTGTTTTGTGTCCGAA-3’ and R-5’-
TGGTTGTGTTCCAGTCTCCA-3’. Fragments were separated on a 2% agarose gel and 
extracted using the Nucleospin gel and PCR clean up (Macherey-Nagel, Düren, Germany). 
The resulting PCR products were sequenced and run on an ABI 3500 genetic analyzer and 
analyzed using the Sequencing Analysis Software 6 (Applied Biosystems).  
 
Antibodies 
Mouse PEN-2 was detected using a polyclonal antibody (B126.2, RRID:AB_2571520) and 
mouse Nicastrin was detected using the monoclonal antibody 9C3 (RRID:AB_2571521), as 
previously described (Chávez-Gutiérrez et al., 2012). Human PSEN1-NTF (RRID: 
AB_11215630) and PSEN1-CTF (RRID:AB_95175) were detected using monoclonal 
antibodies MAB1563 (Chemicon) and MAB5232 (Millipore/Chemicon), respectively. AICD 
was detected using the APP C-terminus antibody B63.3. 
 
Generation of stable cell lines 
Psen1/Psen2 deficient (PSEN1/2
-/-
) mouse embryonic fibroblasts (MEFs) (Herreman et al., 
2000) were cultured in Dulbecco’s modified Eagle’s medium/F-12 containing 10% fetal 
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bovine serum. MEFs were transduced using pMSCV-puro, a replication defective 
recombinant retroviral expression system (Takara Bio Inc.) harboring cDNA inserts coding 
for human wild-type (WT) or mutant PSEN1s, carrying either the deletion of exon 9 (Δ9-
PSEN1) or the deletion of exons 9 and 10 (Δ9-10-PSEN1). Stable cell lines were selected 
using 5µg/mL puromycin (Sigma-Aldrich). 
 
Expression and purification of APP-C99-3xFLAG 
Substrate purification was performed as previously described (Chávez-Gutiérrez et al., 2008). 
Purity was assessed by SDS-PAGE followed by Coomassie staining (GelCode reagent, 
Pierce). 
 
In Vitro Activity Assays using Detergent Extracted γ-Secretase Complexes 
In vitro activity assays were performed as previously described (Chávez-Gutiérrez et al., 
2008) with minor modifications. Briefly, MEF’s microsomal fractions were solubilized in 1% 
CHAPSO. In vitro reactions were carried out in 20 mM Pipes (pH 7.4), 0.15 M NaCl, 0.2 M 
Sucrose, 1 mM EGTA, 1X EDTA-free complete protease inhibitors (Roche), 2.5% DMSO, 
1% phosphatidylcholine and 0.25% CHAPSO. Reactions were incubated for 4 hr at 37°C with 
1.75 µM APP-C99-3xFLAG substrate. The γ-secretase inhibitor “Inhibitor X” was purchased 
from EMD Millipore. 
 
Cell-based assay and Enzyme-Linked ImmunoSorbent Assay 
WT and mutant PSEN1-rescued MEF cell lines were transduced with the recombinant 
adenovirus Ad5/CMV-APP bearing human WT-APP695 as previously described (Chávez-
Gutiérrez et al., 2008). Medium was refreshed seven hours after transduction and extracellular 
media were collected 24 hours later. Aβ38, Aβ40 and Aβ42 levels in extracellular media were 
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quantified on Multi-Spot 96-well plates precoated with anti-Aβ38, -Aβ40 and -Aβ42 using 
MSD technologies (Haryana, India) as previously described (Szaruga et al., 2015). Aβ43 
levels were measured using an Aβ43 ELISA kit (IBL, Männedorf, Switzerland). 
 
RESULTS 
Detection and validation of a PSEN1 exon 9/10 deletion 
Apart from a recurrent duplication of the MAPT locus and a deletion of the ABCA7 gene 
(Le Guennec et al., 2016b), the analysis CNVs by CANOES in the 522 EOAD cases and 
584 controls revealed a deletion of exon 9 and 10 of PSEN1 in patient EXT-313-001. 
QMPSF experiments confirmed the presence of the genomic deletion (Figure 1A). Additional 
QMPSF assays were designed to delineate the boundaries of the deletion, using amplicons 
located in introns 8 and 10 of PSEN1. On the basis of these results, PCR amplification and 
sequencing of the deleted fragment showed that the size of the deletion was 10.1 kb and that 
the two breakpoints were situated within a 24 bp homologous sequence located in introns 8 
and 10, 1 kb distal from exon 9 and 3.4 kb proximal from exon 10, respectively (Figure 1B). 
In silico analysis, using the Repeat Masker program (http://www.repeatmasker.org/), revealed 
that the rearrangement resulted from a homologous Alu-mediated recombination, the Alu 
elements spanning the breakpoints deriving from the Alu Y and Alu-Sx subfamily. Skipping 
of exons 9 and 10 of PSEN1 is predicted to result in an in-frame deletion, but introduces a 
S290W missense mutation at the aberrant exon 8-11 junction. RT-PCR experiments on RNA 
extracted from patient’s blood confirmed the expression of the deleted allele (Figure 1C), 
approximately to the same level as the wild-type allele (Figure 1D). Taken together, we 
retained the following mutation nomenclature: Chr14(GRCh37):g.73671948_73682054del; 
NM_000021.3(PSEN1):c.869-1146_1130-1780del; p.Ser290_Arg377delinsTrp; 
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r.869_1129del, and the following Alu sequence identity: Intron8 g.73671924_g.73671947 
Intron10 g.73682031_g.73682054. 
 
Case report 
The patient presented with progressive cognitive decline associated with spastic paraparesis 
from the age of 56 years. He had no personal medical history. His mother died after a ten-
year course of dementia starting from the age of 50 years. No biomaterials were 
available for the relatives. Upon examination at age 59, the patient presented spasticity of 
the lower limbs with decreased motor strength of the left lower limb, pyramidal signs in all 
four limbs but no upper limb motor deficit. Dystonia as well as extrapyramidal hypertonia of 
the left hand were noted. Mini Mental State Examination scored 22/30, and he presented 
severe episodic memory impairment characterized by failure to encode words during the 
assessment of the free and cued selective reminding test. Frontal assessment battery 
revealed executive function disabilities (score was 12/18) CSF was obtained by lumbar 
puncture and collected and stored in polypropylene tubes. All three CSF AD biomarkers were 
consistent with an AD signature: decreased Aβ42 (153 pg/mL, N>700), increased Total-Tau 
(414 pg/mL, N<350) and Phosphorylated-Tau (64 pg/mL, N<60). Cerebral MRI showed 
severe atrophy predominantly involving the occipital-parietal bilateral cortex in T1-weighted 
sequences. A similar volume loss was found in the medial temporal structures. The cerebral 
fluorodesoxyglucose positron emission tomography (FDG-PET) revealed a severe 
hypometabolism affecting the frontal and occipito-parietal bilateral cortex. No 
arguments were found for a cerebrovascular disease or cerebral amyloid angiopathy, as only 
rare unspecific periventricular hyperintensities were present in the FLAIR sequence and T2*-
weighted images did not reveal any micro or macro hemorrhage.  
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Deletion of exons 9-10 drastically impacts the endopeptidase and carboxypeptidase-like 
activities of PSEN1 
To analyze the effect(s) of the deletion of exons 9 and 10 of PSEN1 (hereafter referred to as 
Δ9-10 deletion) on γ-secretase activity, Psen1/2-/- MEFs were rescued with human WT or Δ9-
10 PSEN1. For comparison purposes, we simultaneously analyzed the well-characterized Δ9 
PSEN1 deletion (Chávez-Gutiérrez et al., 2012) and used the dKO as a negative control. 
Apart from PSEN, a mature and active γ-secretase complex is made up of three additional 
subunits: Nicastrin (NCT), PSEN enhancer 2 (Pen-2) and anterior pharynx 1 (Aph1). 
During the assembly and maturation of the γ-secretase complex, PSEN undergoes 
endoproteolytic cleavage within exon 9, releasing the N- and C-terminal fragments (Lee et al., 
1997). As Δ9, the Δ9-10 PSEN1 is not processed and only full-length mutant PSEN1 could be 
observed on western blot (Figure 2A). The PSEN1-CTF antibody did not stain the Δ9-10 
mutant because it targets the PSEN1 loop, encompassing exons 9 and 10. However, the 
presence of mature Nicastrin (NCT) and Pen-2 at similar levels in the WT and mutant 
conditions strongly indicates that the mutant Δ9-10 PSEN1 still reconstitutes mature γ-
secretase complexes.  
To assess the effects of the Δ9-10 deletion, the endopeptidase activity was evaluated in in 
vitro γ-secretase activity assays, using CHAPSO-solubilized membranes prepared from the 
WT and mutant MEF lines as source of enzyme, and purified APP-C99-3XFlag as substrate.  
Western blot analysis revealed a strong decrease of AICD-3XFlag staining with both Δ9 and 
Δ9-10 PSEN1 compared to WT (Figure 2B). These data indicate that both Δ9 and Δ9-10 
deletions severely compromise the global endopeptidase protease activity.  
With regard to the carboxypeptidase-like γ-secretase function, its efficiency was determined 
in cell-based experiments by ELISA measurement of secreted Aβ isoforms. Expression of 
both Δ9 and Δ9-10 PSEN1 resulted in dramatic reductions of Aβ38, Aβ40 and Aβ42 but 
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increased Aβ43 peptide levels compared to WT (Figure 2C). Remarkably, the exon 9-10 
deletion displayed a higher impact on the carboxypeptidase activity than the Δ9 variant, with 
absence of detectable Aβ38 peptide and stronger reductions in Aβ40 and Aβ42 levels. Mutant 
Aβ product profiles highlight Aβ43 as the major secreted peptide from the Δ9-10 PSEN1 cell 
line (Figure 2D). The extreme effect of the Δ9-10 PSEN1 deletion on the carboxypeptidase γ-
secretase efficiency is better appreciated while analyzing the Aβ40/Aβ43 ratio, which informs 
about the efficiency of the 4
th
 catalytic cleavage that converts Aβ43 into Aβ40 (Figure 2E). 
 
DISCUSSION 
While searching for copy-number variations using exome sequencing data from patients with 
EOAD, we identified a novel genomic deletion overlapping exons 9 and 10 of the PSEN1 
gene, resulting from an Alu-mediated recombination. This in-frame deletion led to the 
production of a shorter isoform of PSEN1 lacking exons 9 and 10, which was found to be 
expressed in patient’s blood at a similar level compared to the WT PSEN1. The Δ9-10 PSEN1 
variant misses the largest intracellular loop that connects the transmembrane domains VI and 
VII that contain the catalytic aspartates of the γ-secretase complex, D257 and D384.  
The patient carrying the Δ9-10 deletion presented progressive cognitive decline 
characterized by impaired episodic memory associated with frontal clinical and imaging 
signs. Evidence of an AD pathophysiological process was provided by all three CSF AD 
biomarkers. Such situation highlights the importance of exploring AD CSF biomarkers 
for any patient with a behavioral fronto-temporal dementia according to current criteria 
(Rascovsky et al., 2011). Cognitive impairment was associated with spastic paraparesis, a 
common feature observed in patients carrying deletions of the single exon 9 of PSEN1 and 
usually associated with cotton-wool plaques at neuropathological examination. The patient 
had a disease onset at 56 years, while his mother was affected at age 50. In this family, ages 
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of onset are within the same ranges as the PSEN1 Δ9 mutation carriers (Karlstrom et al., 
2008). Δ9-associated phenotypes are however known to be highly variable (Karlstrom et al., 
2008), even between individuals from the same pedigree (Smith et al., 2001). 
To assess the consequences of the novel PSEN1 deletion on the function of the γ-secretase 
complex, we performed in vitro cell-free and cell-based γ-secretase activity assays.  
Similar to the Δ9 form, the lack of exons 9 and 10 precluded the auto-endoproteolytic 
cleavage of PSEN1 into NTF and CTF. However, the presence of Pen-2 and mature NCT in 
both Δ9 and Δ9-10 PSEN1-mutant γ-secretase complexes is a strong indication of complex 
assembly and maturation. 
Subsequent analysis of AICD and Aβ levels revealed that the Δ9-10 PSEN1-mutant strongly 
impairs the endopeptidase activity and drastically reduces the efficiency of the 
carboxypeptidase-like cleavages. The effects are indicative of a dysfunction of the γ-secretase 
complex (Chávez-Gutiérrez et al., 2012). Interestingly, the PSEN1- Δ9 and Δ9-10 mutants 
impact similarly the endopeptidase activity, but differ regarding their effect on 
carboxypeptidase-like activity. 
The Δ9-10 allele induces a prominent shift towards production of the longer Aβ43 peptide as 
demonstrated by the decreased Aβ40/Aβ43 ratio in cell-based analyses. In fact, Aβ43 is the 
major peptide secreted from the mutant. Aβ43 has been shown to be potently amyloidogenic 
and neurotoxic in vivo (Saito et al., 2011). Recent data functionally evaluating other 
extremely inactivating AD-linked PSEN1 variations show that, as the Δ9-10 mutant, these 
pathogenic variants elevate Aβ43 secretion compared to the WT allele, supporting the idea 
that the Aβ43 peptide is a disease-relevant specie, even at low concentrations (Veugelen et al., 
2016). 
This work further highlights the involvement of deletions hitting the hydrophilic loop of 
PSEN1, mainly encoded by exons 9 and 10, in EOAD determinism  
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The pathogenic 9 deletion leads to decreased endopeptidase activity, associated with a 
change of carboxypeptidase-like activity illustrated by an increased Aβ42/Aβ38 ratio 
(Chávez-Gutiérrez et al., 2012), while the artificial deletion of exon 10 alone affected the 
carboxypeptidase-like activity of γ-secretase by increasing Aβ42 levels, without impairing the 
endopeptidase function (Wanngren et al., 2010). Thus, our data suggest a synergistic effect for 
the 9-10 deletion that translates into very low global endopeptidase levels and drastic 
changes in Aβ profiles. However, our studies cannot exclude that the effects are fully or 
partially driven by the missense S290W variation at the exon 8-11 junction, as previous work 
suggested that the effect linked to the deletion of PSEN1 exon 9 was mostly due to the 
presence of the missense S290C variation at the aberrant exon8-10 junction (Steiner et al., 
1999).  
Addressing the mechanistic bases of the differential effects observed for the 9, 10 and 9-
10 mutants on γ-secretase function may offer key insights into how the complex protease is 
regulated. Of note, the recent γ-secretase structure in complex with the inhibitor DAPT (Bai et 
al., 2015) shows the Tyr288 and the Gly378 at about 6Å from each other; a linker comprised 
of Ser289 and Trp290 connects these two residues in the Δ9-10 PSEN1 structure (see Figure 
2F). Thus, this particular structure puts closely in the space the exons 8 and 11, and may be 
used to understand the effects of the 9-10 mutation on the protease complex. 
 
In conclusion, we describe in an EOAD patient a novel deletion of the PSEN1 gene 
encompassing both exons 9 and 10, thus resulting in a complete removal of the largest 
intracellular hydrophilic loop. The large deletion, encompassing 87 amino acids, does not 
affect the assembly of a mature protease complex but has an extreme impact on its 
endopeptidase activity. Interestingly, the mutant carboxypeptidase-like activity is also 
strongly impaired and the deleterious mutant effect leads to an incomplete digestion of long 
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Aβ peptides and enhances the production of toxic, aggregation-prone Aβ43. In fact, Aβ43 is 
the main peptide released from the Δ9-10 PSEN1. These results supports the idea that, as 
encountered in most EOAD-linked PSEN1 mutations (Chávez-Gutiérrez et al. 2012), AD-
linked PSEN1 mutations consistently result in impaired carboxypeptidase-like activity and 
most importantly underlines a potential contribution of Aβ43 to AD pathogenesis. 
Genetically, our work (i) further extents the mutation spectrum of EOAD, (ii) demonstrates 
that exons 9 and 10, that are devoid of pathological missense mutations, are sensitive to 
deletions, and (iii) underlines the need to independently screen deletions of exons 9 and 10 in 
familial EOAD cases. 
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Figure legends 
Figure 1. Validation of the PSEN1 genomic deletion overlapping exon 9 and 10. 
A. Quantitative Multiplex PCR of Short Fluorescent fragments (QMPSF). The 
electropherogram of the patient (red) was superposed to a control subject (blue) by adjusting 
peak height to the control amplicon PCBD2. The vertical axis shows fluorescence in arbitrary 
units and the horizontal axis represents the size of the different amplicons in base pairs. 
Arrows indicate the heterozygous deletion detected by a 50% decrease of the corresponding 
peaks. B. Sanger sequencing of the genomic deleted allele. The breakpoints are located into 
intron 8 and 10. Double red arrow indicates the 24 base pairs homologous sequence mediating 
the Alu recombination. C. Sanger sequencing of the cDNA from the deleted allele. D. 
Amplification of WT and 9-10 alleles of PSEN1 by RT-PCR in control individual and 
patient EXT-313-001. Reverse transcriptions without RNA (-RNA) or polymerase (-enzyme) 
were used as controls. Arrows indicate the WT and Δ9-10 cDNAs. 
 
Figure 2. Functional analysis of the endopeptidase and carboxypeptidase activities of γ-
secretase.  
A. Western Blot of γ-secretase components. Nicastrin, PSEN1-NTF, PSEN1-CTF and Pen-2 
protein levels in PSEN1/2
-/-
 MEFs transduced to express human WT, Δ9 and Δ9-10 PSEN1. 
Arrowheads indicate full-length forms of 9 and 9-10 PSEN1. B. Analysis of endopeptidase 
cleavage. Measurements of AICD level for WT, Δ9 and Δ9-10 PSEN1 γ-secretase complex 
after in vitro activity assay in presence or absence of an active site γ-secretase Inhibitor 
(InhX). C. Analysis of secreted Aβ38, Aβ40, Aβ42 and Aβ43 in extracellular media by 
ELISA. D. The corresponding Aβx/total Aβ ratio and E. the corresponding Aβ40/Aβ43 ratio, 
as an indication of γ-secretase processivity. All experiments were repeated three to eight 
times. Graphs show mean ± SD and statistical significance was tested with one way ANOVA 
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and Dunnett’s post-test ****, P<0.0001, *** P<0.001). F. Presenilin 3D structure in complex 
with the inhibitor DAPT (blue) (PDB code: 5FN2). Side chains of active site Asp257 and 
Asp385 are shown and transmembrane (TM) helices are indicated. Tyr 288 (Y288) and 
Gly378 (G378) are connected by Ser289 and Trp290 (S289-W290) in the mutant Δ9-10 
PSEN1 (indicated by red arrow).  
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Highlights 
 
 Copy-number variation analysis from exome data in EOAD patients. 
 Identification of a genomic deletion of exons 9 and 10 of PSEN1. 
 This in-frame deletion results in an increased secretion of Aβ43. 
 These data support the pathogenic role of Aβ43 EOAD pathophysiology. 
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